Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications
Open Access
- 16 June 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 66 (13) , 8484-8497
Abstract
The peptide fragmentof human serum albumin that wasidentifiedas an inhibitor of C-X-C motif chemokine receptor 4(CXCR4), termed EPI-X4, was investigated as a scaffold for the developmentof CXCR4-targeting radio-theragnostics. Derivatives of its truncatedversion JM#21 (ILRWSRKLPCVS) were conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceticacid (DOTA) and tested in Jurkat and Ghost-CXCR4 cells. Ligand-1, -2, -5, -6, -7, -8, and -9 were selected forradiolabeling. Molecular modeling indicated that Lu-177-DOTAincorporation C-terminally did not interfere with the CXCR4 binding.Lipophilicity, in vitro plasma stability, and cellularuptake hinted Lu-177-7 as superior. In Jurkatxenografts, all radioligands showed >90% washout from the bodywithinan hour, with the exception of Lu-177-7 and Lu-177-9. Lu-177-7 demonstratedbest CXCR4-tumor targeting. Ex vivo biodistributionand single-photon emission computed tomography (SPECT)/positron emissiontomography (PET)/CT imaging of Lu-177-7/Ga-68-7 showed the same distribution profile forboth radioligands, characterized by very low uptake in all nontargetedorgans except the kidneys. The data support the feasibility of CXCR4-targetingwith EPI-X4-based radioligands and designate ligand-7 as a lead candidate for further optimization.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030L_192476)
- Deutsche Forschungsgemeinschaft (316249678 SFB 1279, EXC-2033 - 390677874, MU 3115/11-1, MU 3115/8-1)
- Baden-Württemberg Stiftung
- Universität Ulm (L.SBN.0209)
This publication has 46 references indexed in Scilit:
- Molecular Imaging of Chemokine Receptor CXCR4Theranostics, 2013
- Design, Synthesis, and Functionalization of Dimeric Peptides Targeting Chemokine Receptor CXCR4Journal of Medicinal Chemistry, 2011
- PET Imaging of CXCR4 Receptors in Cancer by a New Optimized LigandChemMedChem, 2011
- Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide AntagonistsScience, 2010
- 64Cu-AMD3100—A novel imaging agent for targeting chemokine receptor CXCR4Bioorganic & Medicinal Chemistry, 2009
- Structural Basis of CXCR4 Sulfotyrosine Recognition by the Chemokine SDF-1/CXCL12Science Signaling, 2008
- Chemokine ReceptorCXCR4Expression in Colorectal Cancer Patients Increases the Risk for Recurrence and for Poor SurvivalJournal of Clinical Oncology, 2005
- Cancer and the chemokine networkNature Reviews Cancer, 2004
- Crystal Structures of Two Complexes of the Rare-Earth-DOTA-Binding Antibody 2D12.5: Ligand Generality from a Chiral SystemJournal of the American Chemical Society, 2003
- HADDOCK: A Protein−Protein Docking Approach Based on Biochemical or Biophysical InformationJournal of the American Chemical Society, 2003